Published in Neurology on June 15, 2010
Clinical efficacy of BG-12 (dimethyl fumarate) in patients with relapsing-remitting multiple sclerosis: subgroup analyses of the CONFIRM study. J Neurol (2013) 1.18
Mortality in patients with multiple sclerosis. Neurology (2013) 1.15
Internet portal use in an academic multiple sclerosis center. J Am Med Inform Assoc (2011) 1.00
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies. Neurol Genet (2016) 0.97
Disability in multiple sclerosis: a reference for patients and clinicians. Neurology (2013) 0.96
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol (2011) 0.95
Natural history of multiple sclerosis symptoms. Int J MS Care (2013) 0.93
Health-related quality of life outcomes at 1 and 5 years after a residential retreat promoting lifestyle modification for people with multiple sclerosis. Neurol Sci (2012) 0.91
Prognostic risk estimates of patients with multiple sclerosis and their physicians: comparison to an online analytical risk counseling tool. PLoS One (2013) 0.82
A longitudinal model for disease progression was developed and applied to multiple sclerosis. J Clin Epidemiol (2015) 0.82
Human endogenous retroviruses and the nervous system. Handb Clin Neurol (2014) 0.82
Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int (2015) 0.81
Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. Dis Markers (2013) 0.80
Clinical and demographic factors affecting disease severity in patients with multiple sclerosis. Iran J Neurol (2013) 0.80
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open (2014) 0.80
Clinical baseline factors predict response to natalizumab: their usefulness in patient selection. BMC Neurol (2014) 0.79
Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis. Neuropsychiatr Dis Treat (2013) 0.79
The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. Neurology (2016) 0.78
Cytokines as Biomarkers of Treatment Response to IFN β in Relapsing-Remitting Multiple Sclerosis. Mult Scler Int (2014) 0.78
Practice patterns of US neurologists in patients with SPMS and PPMS: A consensus study. Neurol Clin Pract (2012) 0.78
Patient preferences for treatment of multiple sclerosis with disease-modifying therapies: a discrete choice experiment. Patient Prefer Adherence (2016) 0.78
Multiple sclerosis course and clinical outcomes in patients with comorbid asthma: a survey study. BMJ Open (2015) 0.77
Estimating typical multiple sclerosis disability progression speed from clinical observations. PLoS One (2014) 0.76
Beta-interferon exposure and onset of secondary progressive multiple sclerosis. Eur J Neurol (2015) 0.76
The role of information system in multiple sclerosis management. J Res Med Sci (2014) 0.76
Optical coherence tomography segmentation analysis in relapsing remitting versus progressive multiple sclerosis. PLoS One (2017) 0.75
Children of chronically ill parents: Relationship between parental multiple sclerosis and childhood developmental health. Mult Scler (2015) 0.75
A population-based study comparing multiple sclerosis clinic users and non-users in British Columbia, Canada. Eur J Neurol (2016) 0.75
The Effects of Cognitive Rehabilitation on Relapsing Remitting Multiple Sclerosis Patients. Noro Psikiyatr Ars (2015) 0.75
Dimethyl fumarate in the management of multiple sclerosis: appropriate patient selection and special considerations. Ther Clin Risk Manag (2016) 0.75
Association study of four polymorphisms in the interleukin-7 receptor alpha gene with multiple sclerosis in Eastern Iran. Iran J Basic Med Sci (2015) 0.75
Healthy Aging from the Perspectives of 683 Older People with Multiple Sclerosis. Mult Scler Int (2016) 0.75
Disability Progression in Multiple Sclerosis Is Affected by the Emergence of Comorbid Arterial Hypertension. J Clin Neurol (2016) 0.75
The Liberation Procedure Decision-Making Experience for People With Multiple Sclerosis. Glob Qual Nurs Res (2014) 0.75
Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals. Neuroimage Clin (2017) 0.75
[Multiple sclerosis : rehabilitation and long-term course]. Ophthalmologe (2014) 0.75
Magnetic resonance imaging perfusion is associated with disease severity and activity in multiple sclerosis. Neuroradiology (2017) 0.75
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med (2012) 6.51
Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA (2012) 5.11
A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med (2010) 4.08
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol (2009) 2.82
A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler (2012) 2.16
Translation initiator EIF4G1 mutations in familial Parkinson disease. Am J Hum Genet (2011) 2.00
Yet another flawed study of self-referral? AJR Am J Roentgenol (2012) 1.98
CNTF is a major protective factor in demyelinating CNS disease: a neurotrophic cytokine as modulator in neuroinflammation. Nat Med (2002) 1.91
The natural history of secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2010) 1.89
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Three times weekly glatiramer acetate in relapsing-remitting multiple sclerosis. Ann Neurol (2013) 1.83
Identification of the SPG15 gene, encoding spastizin, as a frequent cause of complicated autosomal-recessive spastic paraplegia, including Kjellin syndrome. Am J Hum Genet (2008) 1.79
Human endogenous retrovirus type W envelope expression in blood and brain cells provides new insights into multiple sclerosis disease. Mult Scler (2012) 1.77
REEP1 mutation spectrum and genotype/phenotype correlation in hereditary spastic paraplegia type 31. Brain (2008) 1.77
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol (2013) 1.76
Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain (2004) 1.70
Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. Lancet Neurol (2011) 1.69
EPIBLASTER-fast exhaustive two-locus epistasis detection strategy using graphical processing units. Eur J Hum Genet (2010) 1.62
A polymorphism in the human cytotoxic T-lymphocyte antigen 4 ( CTLA4) gene (exon 1 +49) alters T-cell activation. Immunogenetics (2002) 1.58
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol (2003) 1.57
Association of a null mutation in the CNTF gene with early onset of multiple sclerosis. Arch Neurol (2002) 1.53
A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann Neurol (2005) 1.50
Natural, innate improvements in multiple sclerosis disability. Mult Scler (2012) 1.50
Exhaustive analysis of BH4 and dopamine biosynthesis genes in patients with Dopa-responsive dystonia. Brain (2009) 1.44
Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. Dtsch Arztebl Int (2008) 1.33
Cytokine mRNA expression in patients with multiple sclerosis and fatigue. Mult Scler (2004) 1.24
Human endogenous retrovirus (HERV)-W ENV and GAG proteins: physiological expression in human brain and pathophysiological modulation in multiple sclerosis lesions. J Neurovirol (2005) 1.19
Does natalizumab therapy worsen neuromyelitis optica? Neurology (2012) 1.19
Evidence for VAV2 and ZNF433 as susceptibility genes for multiple sclerosis. J Neuroimmunol (2010) 1.12
Tyrosine kinase 2 variant influences T lymphocyte polarization and multiple sclerosis susceptibility. Brain (2011) 1.11
Patient-centered outcomes: translating clinical efficacy into benefits on health-related quality of life. Neurology (2010) 1.10
Interferon beta and long-term disability in multiple sclerosis. JAMA Neurol (2013) 1.08
Characteristic gene expression profile of primary human cerebral endothelial cells. FASEB J (2002) 1.07
Subcutaneous interferon-beta injections in patients with multiple sclerosis initiate inflammatory skin reactions by local chemokine induction. J Neuroimmunol (2005) 1.05
Pharmacogenomics of responsiveness to interferon IFN-beta treatment in multiple sclerosis: a genetic screen of 100 type I interferon-inducible genes. Clin Pharmacol Ther (2005) 1.05
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome. Mult Scler (2012) 1.04
Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades. J Neurooncol (2006) 1.04
The natural history of primary progressive multiple sclerosis. Neurology (2009) 1.02
Interferon-beta1b in multiple sclerosis. Expert Rev Neurother (2007) 1.02
Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol (2009) 1.01
The patient knows best: significant change in the physical component of the Multiple Sclerosis Impact Scale (MSIS-29 physical). J Neurol Neurosurg Psychiatry (2007) 1.01
Evaluation of soluble junctional adhesion molecule-A as a biomarker of human brain endothelial barrier breakdown. PLoS One (2010) 1.00
Clinical outcomes of 90 isolated unilateral facet fractures, subluxations, and dislocations treated surgically and nonoperatively. Spine (Phila Pa 1976) (2007) 1.00
Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol (2002) 0.99
Efficacy of vitamin D3 as add-on therapy in patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon β-1a: a Phase II, multicenter, double-blind, randomized, placebo-controlled trial. J Neurol Sci (2011) 0.98
Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J Neuroimmunol (2006) 0.98
Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler (2011) 0.97
Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis. J Mol Med (Berl) (2005) 0.96
Genome-wide significant association of ANKRD55 rs6859219 and multiple sclerosis risk. J Med Genet (2013) 0.96
Early intervention in multiple sclerosis : better outcomes for patients and society? Drugs (2003) 0.96
[Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)]. Nervenarzt (2006) 0.95
Additional efficacy endpoints from pivotal natalizumab trials in relapsing-remitting MS. J Neurol (2011) 0.95
MANBA, CXCR5, SOX8, RPS6KB1 and ZBTB46 are genetic risk loci for multiple sclerosis. Brain (2013) 0.94
Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother (2008) 0.94
Atorvastatin partially prevents an inflammatory barrier breakdown of cultured human brain endothelial cells at a pharmacologically relevant concentration. J Neurochem (2007) 0.94
Regulation of human endogenous retrovirus W protein expression by herpes simplex virus type 1: implications for multiple sclerosis. J Neurovirol (2006) 0.94
Selective loss of regulatory T cells in thymomas. Ann Neurol (2004) 0.94
Sporadic adult onset dystonia: sensory abnormalities as an endophenotype in unaffected relatives. J Neurol Neurosurg Psychiatry (2007) 0.94
Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer (2006) 0.93
Effects of latitude and longitude on the population structure of Culex pipiens s.l., vectors of West Nile virus in North America. Am J Trop Med Hyg (2009) 0.92
Temporal discrimination, a cervical dystonia endophenotype: penetrance and functional correlates. Mov Disord (2014) 0.92
Interferon-beta is a potent inducer of interferon regulatory factor-1/2-dependent IP-10/CXCL10 expression in primary human endothelial cells. J Vasc Res (2006) 0.92
Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis. J Neuroimmunol (2004) 0.91
Characterising aggressive multiple sclerosis. J Neurol Neurosurg Psychiatry (2013) 0.90
mtDNA nt13708A variant increases the risk of multiple sclerosis. PLoS One (2008) 0.90
Hospital admissions and MS: temporal trends and patient characteristics. Am J Manag Care (2012) 0.90
Leigh disease associated with a novel mitochondrial DNA ND5 mutation. Eur J Hum Genet (2002) 0.89
Sporadic adult onset primary torsion dystonia is a genetic disorder by the temporal discrimination test. Brain (2011) 0.89
TRAIL, CXCL10 and CCL2 plasma levels during long-term Interferon-beta treatment of patients with multiple sclerosis correlate with flu-like adverse effects but do not predict therapeutic response. J Neuroimmunol (2007) 0.88
Multiple sclerosis in the Arabian Gulf countries: a consensus statement. J Neurol (2013) 0.88
Comparing endophenotypes in adult-onset primary torsion dystonia. Mov Disord (2010) 0.87
Downregulation of CXCR1 and CXCR2 expression on human neutrophils by Helicobacter pylori: a new pathomechanism in H. pylori infection? Infect Immun (2004) 0.87
Linkage to a known gene but no mutation identified: comprehensive reanalysis of SPG4 HSP pedigrees reveals large deletions as the sole cause. Hum Mutat (2007) 0.87
Evidence for shoulder girdle dystonia in selected patients with cervical disc prolapse. Mov Disord (2002) 0.87
Genetic polymorphisms, their allele combinations and IFN-beta treatment response in Irish multiple sclerosis patients. Pharmacogenomics (2009) 0.87
A novel CACNA1A mutation associated with adult-onset, paroxysmal head tremor. Mov Disord (2013) 0.87
Symptomatology of MS: results from the German MS Registry. J Neurol (2009) 0.87
Determination of ventricular diameters in multiple sclerosis patients with transcranial sonography (TCS)--a two year follow-up study. J Neurol (2004) 0.86
Further evidence of dementia in SPG4-linked autosomal dominant hereditary spastic paraplegia. Neurology (2004) 0.86
New-onset focal epilepsy with palatal tremor and glutamic acid decarboxylase antibodies responding to intravenous immunoglobulin. J Neurol (2008) 0.86
Paroxysmal torticollis and blepharospasm following bilateral cerebellar infarction. J Neurol (2006) 0.85
Imatinib buys time for brain after stroke. Nat Med (2008) 0.85
Texture analysis differentiates persistent and transient T1 black holes at acute onset in multiple sclerosis: a preliminary study. Mult Scler (2011) 0.85
Population frequency of HLA haplotypes contributes to the prevalence difference of multiple sclerosis in Ireland. J Neurol (2005) 0.85
Factors associated with delay to medical recognition in two Canadian multiple sclerosis cohorts. J Neurol Sci (2010) 0.85
Building up the blood-brain barrier. Nat Med (2003) 0.84
Sensory ataxic neuropathy dysarthria and ophthalmoparesis (SANDO) in a sibling pair with a homozygous p.A467T POLG mutation. Muscle Nerve (2010) 0.84
Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? Mult Scler (2009) 0.84
MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. J Neurol (2012) 0.84
Effects of BG-12 (dimethyl fumarate) on health-related quality of life in patients with relapsing-remitting multiple sclerosis: findings from the CONFIRM study. Mult Scler (2013) 0.83
Production of IL-12 and IL-18 in human dendritic cells upon infection by Listeria monocytogenes. FEMS Immunol Med Microbiol (2003) 0.83
Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis: role of MHC class II and AIRE genes and genetic polymorphisms. Ann N Y Acad Sci (2008) 0.82
A genome wide scan for association with multiple sclerosis in a N. Irish case control population. J Neuroimmunol (2003) 0.82
Cytokine mRNA expression patterns in the disease course of female adolescents with anorexia nervosa. Psychoneuroendocrinology (2004) 0.82
Birth hospitalization in mothers with multiple sclerosis and their newborns. Neurology (2013) 0.82
Adult mosquitoes parasitized by larval water mites in Pennsylvania. J Parasitol (2012) 0.82